The DOI matches its Crossref record; 355 of the 355 references it cites were found in a registry or an index.
Metabolic dysfunction-associated steatotic liver disease in adults
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Self-citationAlberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The nonalcoholic steatohepatitis (NASH) Clinical Research Network grades fibrosis as follows — stage 0, none; stage 1, perisinusoidal fibrosis or portal/periportal fibrosis; stage 2, perisinusoidal and portal/periportal; stage 3, bridging fibrosis; stage 4, cirrhosis 157 .”
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“Several GLP-1 RAs are approved for the treatment of T2DM and obesity and have the additional benefit of reducing major cardiovascular and renal events in those with T2DM and established cardiovascular disease 268,269 .”
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 3×
“…of 247 participants with MASH and without T2DM assigned participants to pioglitazone, vitamin E or placebo for 96 weeks and determined that vitamin E significantly improved histologic features of MASH compared with placebo (43% versus 19%, P = 0.001), but had no significant impact on fibrosis 285 .”
InfluentialMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100 · cited 2×
“Multiple concerns led to the development of a multistakeholder consensus Delphi statement led by the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver and the Asociación Latinoamericana para el Estudio del Hígado 337 .”
Self-citationBaveno VII – Renewing consensus in portal hypertension
de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., Abraldes, J. G., Albillos, A., Baiges, A., Bajaj, J., Bañares, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.022 · Cited by 2,930
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · cited 10×
“…for the study of liver diseases (AASLD) does not recommend conventional ultrasonography as a tool to identify hepatic steatosis owing to its low sensitivity for mild degrees of steatosis and instead recommends the controlled attenuation parameter (CAP) to assess and quantify steatosis 3,148 .”
InfluentialSelf-citationMeta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Self-citationSampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 1×
“Several GLP-1 RAs are approved for the treatment of T2DM and obesity and have the additional benefit of reducing major cardiovascular and renal events in those with T2DM and established cardiovascular disease 268,269 .”
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 1×
“Although tolerability related to gastrointestinal side effects remains a concern, semaglutide has well-established efficacy in the management of T2DM and obesity, and has demonstrated renal and cardiovascular mortality benefits 301,302 .”
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“In a phase IIb trial of biopsy confirmed MASH with stage 1–3 fibrosis, participants who received a once-daily dose of semaglutide (0.4 mg) achieved a 59% MASH resolution, compared with 17% in those who received placebo 20 .”
InfluentialProjected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
Ward, Z. J., Bleich, S. N., Cradock, A. L., Barrett, J. L., Giles, C. M., Flax, C., Long, M. W., & Gortmaker, S. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmsa1909301 · Cited by 2,009 · cited 1×
“The increasing prevalence of MASLD is in part owing to the growing prevalence of type 2 diabetes mellitus (T2DM) and obesity 9,10 .”
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 1,980
Self-citationBerzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Self-citationTGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885 · cited 1×
“Bile acids activate the Takeda G-protein-coupled receptor 5 in L cells in the intestine, stimulating GLP-1, increasing insulin synthesis and decreasing appetite 139 .”
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Self-citationSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Self-citationHernaez, R., Lazo, M., Bonekamp, S., Kamel, I., Brancati, F. L., Guallar, E., & Clark, J. M. (2011) · Hepatology · doi:10.1002/hep.24452 · Cited by 1,585
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483 · cited 2×
“Specific microbial signatures, such as an increase in Akkermansia , Ruminococcus and Bacteroides are associated with MASLD, whereas an increased abundance of Veillonella , Shigella and Bacillus is associated with hepatic fibrosis 133,134 .”
Self-citationMolecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471 · cited 2×
“In addition to oxidation, the export of triglycerides via packaging into VLDL particles is the only other way to reduce hepatic triglyceride content 99 .”
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,424
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421025 · Cited by 1,397
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citationKarlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.022 · Cited by 1,275 · cited 2×
“CAP is well validated for detecting mild hepatic steatosis and is increasingly utilized to provide point-of-care assessment of liver steatosis 149,150 .”
Self-citationKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 2×
“For example, the variant TM6SF2 rs58542926 C > T codes for a loss-of-function E to K substitu-tion at position 167 and is associated with elevated levels of alanine transaminase (ALT) and hepatic steatosis 116,117 .”
Bile acids and the gut microbiota: metabolic interactions and impacts on disease
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D., & Patterson, A. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00805-x · Cited by 1,214
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029349 · Cited by 1,146 · cited 1×
“In a prospective United States study of 1,773 participants with biopsy-confirmed MASLD from 2009 to 2019, participants were followed-up for a median of 4 years and monitored for the development of hepatic and extrahepatic complications 32 .”
Self-citationWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128 · cited 1×
“Of note, GLP-1 RA withdrawal is associated with substantial regain of lost weight, suggesting that long-term treatment may be needed, but long-term adherence may be challenging given that real-world studies have demonstrated that >30% of people withdraw from treatment within the first year 275–277 .”
New trends on obesity and NAFLD in Asia
Fan, J.-G., Kim, S.-U., & Wong, V. W.-S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.003 · Cited by 1,083
Self-citationLambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · cited 1×
“Lipolysis in peripheral adipose tissue or dietary sugars or amino acids that are converted to saturated fatty acids via hepatic de novo lipogenesis contributes to the formation of intrahepatic triglycerides 80,81 .”
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,063
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationTirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Self-citationEisenberg, D., Shikora, S. A., Aarts, E., Aminian, A., Angrisani, L., Cohen, R. V., De Luca, M., Faria, S. L., Goodpaster, K. P. S., Haddad, A., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.08.013 · Cited by 985 · cited 1×
“…recommending a threshold of BMI ≥40–50 kg/m 2 or BMI ≥35 kg/m 2 with comorbidities, whereas several Asian societies such as the Korean Society for the Management of Obesity and the Chinese Diabetes Society have proposed lower BMI thresholds (≥27.5 kg/m 2 ) in the presence of comorbidities 251–254 .”
InfluentialGenetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 953
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
Jensen, T., Abdelmalek, M. F., Sullivan, S., Nadeau, K. J., Green, M., Roncal, C., Nakagawa, T., Kuwabara, M., Sato, Y., Kang, D.-H., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.019 · Cited by 941
Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925
Self-citationFructose consumption as a risk factor for non-alcoholic fatty liver disease
Ouyang, X., Cirillo, P., Sautin, Y., McCall, S., Bruchette, J. L., Diehl, A. M., Johnson, R. J., & Abdelmalek, M. F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.02.011 · Cited by 863
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 852
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101133 · Cited by 844
Self-citationGlobal epidemiology of cirrhosis — aetiology, trends and predictions
Huang, D. Q., Terrault, N. A., Tacke, F., Gluud, L. L., Arrese, M., Bugianesi, E., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00759-2 · Cited by 839
Self-citationEslam, M., Sarin, S. K., Wong, V. W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M.-H., Shiha, G., Yilmaz, Y., Gani, R., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 833
Self-citationA Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827 · cited 1×
“…study in 2018 determined that a splice variant (rs72613567) in HSD17B13 , with an estimated minor allele frequency of 18%, disrupts mRNA splicing and generates unstable proteins with reduced activity, which confers a protective effect against the development of MASH and advanced fibrosis 122,123 .”
Imajo, K., Kessoku, T., Honda, Y., Tomeno, W., Ogawa, Y., Mawatari, H., Fujita, K., Yoneda, M., Taguri, M., Hyogo, H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.11.048 · Cited by 812
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801
Self-citationNewsome, P. N., Sasso, M., Deeks, J. J., Paredes, A., Boursier, J., Chan, W.-K., Yilmaz, Y., Czernichow, S., Zheng, M.-H., Wong, V. W.-S., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30383-8 · Cited by 800
Self-citationAdvancing the global public health agenda for NAFLD: a consensus statement
Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00523-4 · Cited by 757
Self-citationMolecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
Hoyles, L., Fernández-Real, J.-M., Federici, M., Serino, M., Abbott, J., Charpentier, J., Heymes, C., Luque, J. L., Anthony, E., Barton, R. H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0061-3 · Cited by 720 · cited 1×
“Multiple studies have demonstrated an association between gut microbial dysbiosis and the development and severity of MASLD and hepatic fibrosis 132,133 .”
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Self-citationPark, C. C., Nguyen, P., Hernandez, C., Bettencourt, R., Ramirez, K., Fortney, L., Hooker, J., Sy, E., Savides, M. T., Alquiraish, M. H., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.026 · Cited by 708
Self-citationStandards of medical care for type 2 diabetes in China 2019
Jia, W., Weng, J., Zhu, D., Ji, L., Lu, J., Zhou, Z., Zou, D., Guo, L., Ji, Q., Chen, L., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3158 · Cited by 700
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea
Seo, M. H., Lee, W.-Y., Kim, S. S., Kang, J.-H., Kang, J.-H., Kim, K. K., Kim, B.-Y., Kim, Y.-H., Kim, W.-J., Kim, E. M., et al. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.1.40 · Cited by 676
Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00308-3 · Cited by 674
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634
Fabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631
Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.006 · Cited by 622
Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618
Self-citationSiddiqui, M. S., Vuppalanchi, R., Van Natta, M. L., Hallinan, E., Kowdley, K. V., Abdelmalek, M., Neuschwander-Tetri, B. A., Loomba, R., Dasarathy, S., Brandman, D., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.043 · Cited by 614
Self-citationThe therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Geng, L., Lam, K. S. L., & Xu, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0386-0 · Cited by 607 · cited 1×
“FGF19 and FGF21 are hormones that regulate energy expenditure and glucose and lipid homeostasis 303 .”
Inflammasome activation and function in liver disease
Szabo, G., & Petrasek, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.94 · Cited by 597
Zhou, F., Zhou, J., Wang, W., Zhang, X., Ji, Y., Zhang, P., She, Z., Zhu, L., Cai, J., & Li, H. (2019) · Hepatology · doi:10.1002/hep.30702 · Cited by 582
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Buch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565 · cited 1×
“A variant in MBOAT7 at rs641738, with an estimated minor allele frequency of 45%, was associated with an increased risk of steatosis and fibrosis in MASLD 119,120 .”
Mózes, F. E., Lee, J. A., Selvaraj, E. A., Jayaswal, A. N. A., Trauner, M., Boursier, J., Fournier, C., Staufer, K., Stauber, R. E., Bugianesi, E., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324243 · Cited by 556
Self-citationExome-wide association study of plasma lipids in >300,000 individuals
Charge Diabetes Working Group, Liu, D. J., The EPIC-InterAct Consortium, EPIC-CVD Consortium, GOLD Consortium, Program, V. M. V., Peloso, G. M., Yu, H., Butterworth, A. S., Wang, X., et al. (2017) · Nature Genetics · doi:10.1038/ng.3977 · Cited by 540
Huang, D. Q., Singal, A. G., Kono, Y., Tan, D. J. H., El-Serag, H. B., & Loomba, R. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.003 · Cited by 534
Self-citationLoomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533
Self-citationA Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522
Self-citationSyn, N. L., Cummings, D. E., Wang, L. Z., Lin, D. J., Zhao, J. J., Loh, M., Koh, Z. J., Chew, C. A., Loo, Y. E., Tai, B. C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00591-2 · Cited by 521
Cassinotto, C., Boursier, J., de Lédinghen, V., Lebigot, J., Lapuyade, B., Cales, P., Hiriart, J., Michalak, S., Bail, B. L., Cartier, V., et al. (2016) · Hepatology · doi:10.1002/hep.28394 · Cited by 521
Self-citationGastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
Harrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.027 · Cited by 497
Self-citationYounossi, Z. M., Corey, K. E., & Lim, J. K. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.051 · Cited by 490
Rich, N. E., Oji, S., Mufti, A. R., Browning, J. D., Parikh, N. D., Odewole, M., Mayo, H., & Singal, A. G. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.09.041 · Cited by 486
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Luukkonen, P. K., Zhou, Y., Sädevirta, S., Leivonen, M., Arola, J., Orešič, M., Hyötyläinen, T., & Yki-Järvinen, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.002 · Cited by 461
Self-citationLomonaco, R., Ortiz-Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., Finch, J., Gastaldelli, A., Harrison, S., Tio, F., et al. (2012) · Hepatology · doi:10.1002/hep.25539 · Cited by 459
NAFLD as a driver of chronic kidney disease
Byrne, C. D., & Targher, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.013 · Cited by 449
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
Davison, B. A., Harrison, S. A., Cotter, G., Alkhouri, N., Sanyal, A., Edwards, C., Colca, J. R., Iwashita, J., Koch, G. G., & Dittrich, H. C. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.025 · Cited by 448
MAFLD: How is it different from NAFLD?
Gofton, C., Upendran, Y., Zheng, M.-H., & George, J. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0367 · Cited by 423
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
Younossi, Z. M., Rinella, M. E., Sanyal, A. J., Harrison, S. A., Brunt, E. M., Goodman, Z., Cohen, D. E., & Loomba, R. (2021) · Hepatology · doi:10.1002/hep.31420 · Cited by 417
Self-citationTosello-Trampont, A.-C., Landes, S. G., Nguyen, V., Novobrantseva, T. I., & Hahn, Y. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417014 · Cited by 415
Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
Parthasarathy, G., Revelo, X., & Malhi, H. (2020) · Hepatology Communications · doi:10.1002/hep4.1479 · Cited by 414
Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci
Stender, S., Kozlitina, J., Nordestgaard, B. G., Tybjærg-Hansen, A., Hobbs, H. H., & Cohen, J. C. (2017) · Nature Genetics · doi:10.1038/ng.3855 · Cited by 400
Kanwal, F., Neuschwander-Tetri, B. A., Loomba, R., & Rinella, M. E. (2024) · Hepatology · doi:10.1097/hep.0000000000000670 · Cited by 388
Self-citationBianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.024 · Cited by 385 · cited 1×
“…to their modest accuracy for prognostication, the lack of calibration in different settings and in vitro diagnostic device labelling, difficulties in reimbursement, a lack of knowledge and guidance among disease specialists, and the influence of epigenetics and environmental factors 129–131 .”
Harrison, S. A., Abdelmalek, M. F., Caldwell, S., Shiffman, M. L., Diehl, A. M., Ghalib, R., Lawitz, E. J., Rockey, D. C., Schall, R. A., Jia, C., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.006 · Cited by 384
En Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330110 · Cited by 380 · cited 2×
“A meta-analysis of 156 studies estimated that 65% of people with T2DM have MASLD 39 .”
Self-citationSelvaraj, E. A., Mózes, F. E., Jayaswal, A. N. A., Zafarmand, M. H., Vali, Y., Lee, J. A., Levick, C. K., Young, L. A. J., Palaniyappan, N., Liu, C.-H., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.044 · Cited by 376 · cited 2×
“…liver stiffness based on tissue displacement from acoustic compression pulses and has comparable diagnostic performance to transient elastography, but requires technical expertise and is complicated by differing shear wave speeds between vendors, limiting comparison between studies 178,179 .”
InfluentialAminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375 · cited 1×
“A retrospective cohort study of 1,158 patients with severe obesity who underwent liver biopsy determined that bariatric surgery was associated with a lower risk of major adverse liver outcomes and major adverse cardiovascular events than a non-surgical control group 16 .”
Caussy, C., Alquiraish, M. H., Nguyen, P., Hernandez, C., Cepin, S., Fortney, L. E., Ajmera, V., Bettencourt, R., Collier, S., Hooker, J., et al. (2018) · Hepatology · doi:10.1002/hep.29639 · Cited by 375
Self-citationCan we use old NAFLD data under the new MASLD definition?
Song, S. J., Lai, J. C.-T., Wong, G. L.-H., Wong, V. W.-S., & Yip, T. C.-F. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.021 · Cited by 374
Self-citationAdaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374 · cited 1×
“…sphingolipids (including cera-mides) and sphingosine 1-phosphate in people with MASLD contributes to endoplasmic reticulum stress, hepatocellular injury and death, activation of inflammasomes (such as NLRP3) and toll-like receptors, immune cell-mediated inflammation and fibrosis 100–102 .”
Association of histologic disease activity with progression of nonalcoholic fatty liver disease
Kleiner, D. E., Brunt, E. M., Wilson, L. A., Behling, C., Guy, C., Contos, M., Cummings, O., Yeh, M., Gill, R., Chalasani, N., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.12565 · Cited by 372
Self-citationAllen, A. M., Therneau, T. M., Larson, J. J., Coward, A., Somers, V. K., & Kamath, P. S. (2018) · Hepatology · doi:10.1002/hep.29546 · Cited by 370
Kohjima, M., Higuchi, N., Kato, M., Kotoh, K., Yoshimoto, T., Fujino, T., Yada, M., Yada, R., Harada, N., Enjoji, M., et al. (2008) · International Journal of Molecular Medicine · doi:10.3892/ijmm.21.4.507 · Cited by 365
Verrastro, O., Panunzi, S., Castagneto-Gissey, L., De Gaetano, A., Lembo, E., Capristo, E., Guidone, C., Angelini, G., Pennestrì, F., Sessa, L., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00634-7 · Cited by 362
Epidemiology and risk-stratification of NAFLD-associated HCC
Ioannou, G. N. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.012 · Cited by 361
Global developments in social prescribing
Morse, D. F., Sandhu, S., Mulligan, K., Tierney, S., Polley, M., Chiva Giurca, B., Slade, S., Dias, S., Mahtani, K. R., Wells, L., et al. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-008524 · Cited by 359
Tang, A., Desai, A., Hamilton, G., Wolfson, T., Gamst, A., Lam, J., Clark, L., Hooker, J., Chavez, T., Ang, B. D., et al. (2015) · Radiology · doi:10.1148/radiol.14140754 · Cited by 356
Self-citationNonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, A. W.-H., Chermak, F., Choi, P. C.-L., Merrouche, W., Chu, S. H.-T., Pesque, S., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.331 · Cited by 345 · cited 1×
“…measurements by VCTE are increased in the setting of inflammation, recent food intake, heart failure and obesity, and scan failure rates of 3–5% have been reported when the extra-large probe, catered for individuals with obesity, was used, but up to 14% when only the M probe was used 174–176 .”
Self-citationWong, V. W.-S., Chan, R. S.-M., Wong, G. L.-H., Cheung, B. H.-K., Chu, W. C.-W., Yeung, D. K.-W., Chim, A. M.-L., Lai, J. W.-Y., Li, L. S., Sea, M. M.-M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.013 · Cited by 345
Self-citation2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea
Kim, B.-Y., Kang, S. M., Kang, J.-H., Kang, S. Y., Kim, K. K., Kim, K.-B., Kim, B., Kim, S. J., Kim, Y.-H., Kim, J.-H., et al. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21022 · Cited by 342
Stine, J. G., Wentworth, B. J., Zimmet, A., Rinella, M. E., Loomba, R., Caldwell, S. H., & Argo, C. K. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14937 · Cited by 336
Self-citationWong, V. W.-S., Wong, G. L.-H., Chan, R. S.-M., Shu, S. S.-T., Cheung, B. H.-K., Li, L. S., Chim, A. M.-L., Chan, C. K.-M., Leung, J. K.-Y., Chu, W. C.-W., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.08.011 · Cited by 319 · cited 1×
“Of note, weight loss may be beneficial in people with non-obese MASLD, with a randomized trial in Hong Kong demonstrating that a 3–5% weight reduction in individuals with normal weight achieved similar results in terms of MASLD remission to a 7–10% weight reduction in individuals with obesity 233 .”
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315 · cited 1×
“A phase IIa trial of retatrutide, a triple agonist of the GIP, GLP-1 and glucagon receptors, demonstrated that ~20% weight loss was associated with a near-maximal reduction in liver fat, with a plateau beyond 20% weight loss 234 .”
Ma, Y., Belyaeva, O. V., Brown, P. M., Fujita, K., Valles, K., Karki, S., de Boer, Y. S., Koh, C., Chen, Y., Du, X., et al. (2019) · Hepatology · doi:10.1002/hep.30350 · Cited by 312
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310 · cited 1×
“MASLD generally progresses slowly over years from steatosis to cirrhosis, but the presence of risk factors such as T2DM, certain genetic polymorphisms and obesity may accelerate disease progression 11–13 .”
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
Eslam, M., & George, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0212-0 · Cited by 308
Tan, D. J. H., Ng, C. H., Lin, S. Y., Pan, X. H., Tay, P., Lim, W. H., Teng, M., Syn, N., Lim, G., Yong, J. N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00078-x · Cited by 307 · cited 20×
“More than 30% of MASLD-related HCC occurs in people without cirrhosis 5 .”
InfluentialSelf-citationLe, M. H., Le, D. M., Baez, T. C., Wu, Y., Ito, T., Lee, E. Y., Lee, K., Stave, C. D., Henry, L., Barnett, S. D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.040 · Cited by 303 · cited 2×
“MASLD incidence was higher in men than women (5,944 per 100,000 person-years versus 3,672 per 100,000 person-years, P 0.0001) 26 .”
InfluentialLow Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population
Graupera, I., Thiele, M., Serra-Burriel, M., Caballeria, L., Roulot, D., Wong, G. L.-H., Fabrellas, N., Guha, I. N., Arslanow, A., Expósito, C., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.034 · Cited by 295
Self-citationDietary carbohydrates and fats in nonalcoholic fatty liver disease
Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00472-y · Cited by 294
Self-citationNevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Stine, J. G., Munaganuru, N., Barnard, A., Wang, J. L., Kaulback, K., Argo, C. K., Singh, S., Fowler, K. J., Sirlin, C. B., & Loomba, R. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.061 · Cited by 283
Self-citationLifestyle interventions in nonalcoholic fatty liver disease
Younossi, Z. M., Zelber-Sagi, S., Henry, L., & Gerber, L. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00800-4 · Cited by 281
Harrison, S. A., Frias, J. P., Neff, G., Abrams, G. A., Lucas, K. J., Sanchez, W., Gogia, S., Sheikh, M. Y., Behling, C., Bedossa, P., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00272-8 · Cited by 276
Daniels, S. J., Leeming, D. J., Eslam, M., Hashem, A. M., Nielsen, M. J., Krag, A., Karsdal, M. A., Grove, J. I., Neil Guha, I., Kawaguchi, T., et al. (2019) · Hepatology · doi:10.1002/hep.30163 · Cited by 273 · cited 1×
“…ADAPT, which combined PRO-C3 (a marker of type III collagen formation) with age, T2DM and platelet count, demonstrated superior performance to the aspartate aminotransferase–platelet ratio index, FIB-4 and NAFLD fibrosis score for detecting advanced fibrosis, but requires further validation 169 .”
Thiele, M., Madsen, B. S., Hansen, J. F., Detlefsen, S., Antonsen, S., & Krag, A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.005 · Cited by 272
Sinha, R. A., Bruinstroop, E., Singh, B. K., & Yen, P. M. (2019) · Thyroid · doi:10.1089/thy.2018.0664 · Cited by 271
Åberg, F., Helenius‐Hietala, J., Puukka, P., Färkkilä, M., & Jula, A. (2018) · Hepatology · doi:10.1002/hep.29631 · Cited by 267 · cited 1×
“…and mortality among people with MASLD, especially in women, and the AASLD has recommended that people with MASLD and fibrosis stage ≥2 abstain completely from alcohol, whereas the EASL recommends that all alcohol consumption should be stopped completely in people with advanced fibrosis 2,244–246 .”
Lazarus, J. V., Mark, H. E., Villota-Rivas, M., Palayew, A., Carrieri, P., Colombo, M., Ekstedt, M., Esmat, G., George, J., Marchesini, G., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.025 · Cited by 267
Self-citationNon-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
Self-citationVuppalanchi, R., Siddiqui, M. S., Van Natta, M. L., Hallinan, E., Brandman, D., Kowdley, K., Neuschwander‐Tetri, B. A., Loomba, R., Dasarathy, S., Abdelmalek, M., et al. (2018) · Hepatology · doi:10.1002/hep.29489 · Cited by 260
Self-citationHarrison, S. A., Ratziu, V., Boursier, J., Francque, S., Bedossa, P., Majd, Z., Cordonnier, G., Sudrik, F. B., Darteil, R., Liebe, R., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30252-1 · Cited by 255
Self-citationAlexander, M., Loomis, A. K., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., Mosseveld, M., et al. (2019) · BMJ · doi:10.1136/bmj.l5367 · Cited by 254 · cited 1×
“However, a cohort study of 17.7 million patients with MASLD did not find an association between MASLD and acute myocardial infarction or stroke, after adjusting for cardiovascular risk factors such as blood pressure, T2DM and dyslipidaemia 71 .”
InfluentialLin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., et al. (2024) · JAMA · doi:10.1001/jama.2024.1447 · Cited by 250 · cited 2×
“199).”
Self-citationCausal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping
Liu, Z., Zhang, Y., Graham, S., Wang, X., Cai, D., Huang, M., Pique-Regi, R., Dong, X. C., Chen, Y. E., Willer, C., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.006 · Cited by 248
Moore, M. P., Cunningham, R. P., Meers, G. M., Johnson, S. A., Wheeler, A. A., Ganga, R. R., Spencer, N. M., Pitt, J. B., Diaz‐Arias, A., Swi, A. I. A., et al. (2022) · Hepatology · doi:10.1002/hep.32324 · Cited by 240
Health disparities in chronic liver disease
Kardashian, A., Serper, M., Terrault, N., & Nephew, L. D. (2023) · Hepatology · doi:10.1002/hep.32743 · Cited by 239
Multiomics study of nonalcoholic fatty liver disease
Sveinbjornsson, G., Ulfarsson, M. O., Thorolfsdottir, R. B., Jonsson, B. A., Einarsson, E., Gunnlaugsson, G., Rognvaldsson, S., Arnar, D. O., Baldvinsson, M., Bjarnason, R. G., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01199-5 · Cited by 236
Liver cancer in 2021: Global Burden of Disease study
Tan, E. Y., Danpanichkul, P., Yong, J. N., Yu, Z., Tan, D. J. H., Lim, W. H., Koh, B., Lim, R. Y. Z., Tham, E. K. J., Mitra, K., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.031 · Cited by 232
Self-citationSargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231
Impact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
Self-citationVali, Y., Lee, J., Boursier, J., Petta, S., Wonders, K., Tiniakos, D., Bedossa, P., Geier, A., Francque, S., Allison, M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00017-1 · Cited by 224
Self-citationThiele, M., Detlefsen, S., Sevelsted Møller, L., Madsen, B. S., Fuglsang Hansen, J., Fialla, A. D., Trebicka, J., & Krag, A. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.09.040 · Cited by 223
Sanyal, A. J., Foucquier, J., Younossi, Z. M., Harrison, S. A., Newsome, P. N., Chan, W.-K., Yilmaz, Y., De Ledinghen, V., Costentin, C., Zheng, M.-H., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.034 · Cited by 219
Self-citationOrci, L. A., Sanduzzi-Zamparelli, M., Caballol, B., Sapena, V., Colucci, N., Torres, F., Bruix, J., Reig, M., & Toso, C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.002 · Cited by 218 · cited 1×
“The incidence of HCC estimated to be 3.8 per 100 person-years in individuals with MASLD-related cirrhosis and 0.03 per 100 person-years among people with non-cirrhotic MASLD 52 .”
InfluentialNg, C. H., Lim, W. H., Hui Lim, G. E., Hao Tan, D. J., Syn, N., Muthiah, M. D., Huang, D. Q., & Loomba, R. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.04.014 · Cited by 217
Self-citationChen, Y., Du, X., Kuppa, A., Feitosa, M. F., Bielak, L. F., O’Connell, J. R., Musani, S. K., Guo, X., Kahali, B., Chen, V. L., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01497-6 · Cited by 215
Sterling, R. K., Duarte-Rojo, A., Patel, K., Asrani, S. K., Alsawas, M., Dranoff, J. A., Fiel, M. I., Murad, M. H., Leung, D. H., Levine, D., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000000843 · Cited by 215
Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00141-3 · Cited by 214 · cited 2×
“NITs are risk free, some tests have reasonable accuracy for steatosis and fibrosis, especially when following clinical practice guidelines, and many have been validated in large cohorts 143,144 .”
Self-citationSterling, R. K., Patel, K., Duarte‐Rojo, A., Asrani, S. K., Alsawas, M., Dranoff, J. A., Fiel, M. I., Murad, M. H., Leung, D. H., Levine, D., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000845 · Cited by 213
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211 · cited 1×
“Together with GLP-1 RAs, newer combinations of glucagon agonists have been evaluated and demonstrated synergism in achieving weight loss, reductions in oxidative stress and hepatic steatosis, and improvements in insulin profile 283 .”
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207 · cited 1×
“The implications of alcohol consumption in people with MASLD have been reviewed elsewhere 247 .”
Boursier, J., Hagström, H., Ekstedt, M., Moreau, C., Bonacci, M., Cure, S., Ampuero, J., Nasr, P., Tallab, L., Canivet, C. M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.031 · Cited by 206 · cited 1×
“A study of 1,057 patients with MASLD determined that a stepwise approach of FIB-4 followed by VCTE was able to accurately stratify the risk of liver-related events 203 .”
Self-citationChen, V. L., Morgan, T. R., Rotman, Y., Patton, H. M., Cusi, K., Kanwal, F., & Kim, W. R. (2025) · Hepatology · doi:10.1097/hep.0000000000001112 · Cited by 205
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
Noureddin, M., Truong, E., Gornbein, J. A., Saouaf, R., Guindi, M., Todo, T., Noureddin, N., Yang, J. D., Harrison, S. A., & Alkhouri, N. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.012 · Cited by 203
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease
Hagström, H., Talbäck, M., Andreasson, A., Walldius, G., & Hammar, N. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.007 · Cited by 199
Petta, S., Sebastiani, G., Viganò, M., Ampuero, J., Wai-Sun Wong, V., Boursier, J., Berzigotti, A., Bugianesi, E., Fracanzani, A. L., Cammà, C., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.045 · Cited by 197
Taylor‐Weiner, A., Pokkalla, H., Han, L., Jia, C., Huss, R., Chung, C., Elliott, H., Glass, B., Pethia, K., Carrasco‐Zevallos, O., et al. (2021) · Hepatology · doi:10.1002/hep.31750 · Cited by 195
Self-citationCombination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Dufour, J.-F., Caussy, C., & Loomba, R. (2020) · Gut · doi:10.1136/gutjnl-2019-319104 · Cited by 193 · cited 1×
“Combination therapies, coupled with non-pharmaceutical interventions, are likely to become the cornerstone of treatment for MASH by targeting synergistic pathways and lowering toxicity 335 .”
Self-citationVilar‐Gomez, E., Vuppalanchi, R., Gawrieh, S., Ghabril, M., Saxena, R., Cummings, O. W., & Chalasani, N. (2020) · Hepatology · doi:10.1002/hep.30368 · Cited by 193
Abdelmalek, M. F., Lazo, M., Horska, A., Bonekamp, S., Lipkin, E. W., Balasubramanyam, A., Bantle, J. P., Johnson, R. J., Diehl, A. M., & Clark, J. M. (2012) · Hepatology · doi:10.1002/hep.25741 · Cited by 190 · cited 2×
“Unlike in glucose metabolism, no negative feedback mechanism regulates fructose phosphorylation 87 .”
Staufer, K., Huber-Schönauer, U., Strebinger, G., Pimingstorfer, P., Suesse, S., Scherzer, T.-M., Paulweber, B., Ferenci, P., Stimpfl, T., Yegles, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.040 · Cited by 190
Current therapies and new developments in NASH
Dufour, J.-F., Anstee, Q. M., Bugianesi, E., Harrison, S., Loomba, R., Paradis, V., Tilg, H., Wong, V. W.-S., & Zelber-sagi, S. (2022) · Gut · doi:10.1136/gutjnl-2021-326874 · Cited by 190
Self-citationHuang, D. Q., Wilson, L. A., Behling, C., Kleiner, D. E., Kowdley, K. V., Dasarathy, S., Amangurbanova, M., Terrault, N. A., Diehl, A. M., Chalasani, N., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.04.025 · Cited by 190
Self-citationHuang, D. Q., Noureddin, N., Ajmera, V., Amangurbanova, M., Bettencourt, R., Truong, E., Gidener, T., Siddiqi, H., Majzoub, A. M., Nayfeh, T., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00157-7 · Cited by 184
Self-citationMak, L.-Y., Liu, K., Chirapongsathorn, S., Yew, K. C., Tamaki, N., Rajaram, R. B., Panlilio, M. T., Lui, R., Lee, H. W., Lai, J. C.-T., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00967-4 · Cited by 182
Self-citationLuukkonen, P. K., Zhou, Y., Hyötyläinen, T., Leivonen, M., Arola, J., Orho-Melander, M., Orešič, M., & Yki-Järvinen, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.045 · Cited by 179
Self-citationAnstee, Q. M., Neuschwander-Tetri, B. A., Wai-Sun Wong, V., Abdelmalek, M. F., Rodriguez-Araujo, G., Landgren, H., Park, G. S., Bedossa, P., Alkhouri, N., Tacke, F., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.003 · Cited by 179
Arab, J. P., Díaz, L. A., Rehm, J., Im, G., Arrese, M., Kamath, P. S., Lucey, M. R., Mellinger, J., Thiele, M., Thursz, M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.11.028 · Cited by 179
Chen, J., Yin, M., Talwalkar, J. A., Oudry, J., Glaser, K. J., Smyrk, T. C., Miette, V., Sandrin, L., & Ehman, R. L. (2017) · Radiology · doi:10.1148/radiol.2016160685 · Cited by 175
Israelsen, M., Torp, N., Johansen, S., Hansen, C. D., Hansen, E. D., Thorhauge, K., Hansen, J. K., Villesen, I., Bech, K., Wernberg, C., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00443-0 · Cited by 174 · cited 1×
“…and mortality among people with MASLD, especially in women, and the AASLD has recommended that people with MASLD and fibrosis stage ≥2 abstain completely from alcohol, whereas the EASL recommends that all alcohol consumption should be stopped completely in people with advanced fibrosis 2,244–246 .”
Self-citationBoursier, J., Guillaume, M., Leroy, V., Irlès, M., Roux, M., Lannes, A., Foucher, J., Zuberbuhler, F., Delabaudière, C., Barthelon, J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.020 · Cited by 174
Self-citationSerra-Burriel, M., Juanola, A., Serra-Burriel, F., Thiele, M., Graupera, I., Pose, E., Pera, G., Grgurevic, I., Caballeria, L., Piano, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01174-1 · Cited by 171
Self-citationLuukkonen, P. K., Qadri, S., Ahlholm, N., Porthan, K., Männistö, V., Sammalkorpi, H., Penttilä, A. K., Hakkarainen, A., Lehtimäki, T. E., Gaggini, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.013 · Cited by 170
Self-citationBode, J. C., Zelder, O., Rumpelt, H. J., & Wittkampy, U. (1973) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1973.tb02211.x · Cited by 169
Anstee, Q. M., Berentzen, T. L., Nitze, L. M., Jara, M., Jensen, A. B., Kjær, M. S., Mangla, K. K., Tarp, J. M., & Khunti, K. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100780 · Cited by 168
Brunt, E. M., Neuschwander-Tetri, B. A., Oliver, D., Wehmeier, K. R., & Bacon, B. R. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.04.017 · Cited by 167
Cited by
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Self-citationLoomba, R., Daniel, P. C.-Y. N., Amangurbanova, M., Bettencourt, R., Madamba, E., Siddiqi, H., Richards, L., Gottwald, M. D., Feng, S., Margalit, M., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001396 · Cited by 17
Self-citationRegulatory T cells safeguard liver health during metabolic-associated steatohepatitis
Hanna, B. S., Langston, P. K., Marin-Rodero, M., Ramirez, R. N., Wan, M., Benoist, C., & Mathis, D. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536314123 · Cited by 1
“M etabolic - dysfunction - a ssociated s teatoh epatitis (MASH) is a related but distinct inflammatory complication of the metabolic syndrome, characterized by steatosis, hepatocellular injury, immunocyte accumulation, and progressive fibrosis (11).”
Metadata
- Authors
- Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R.
- Venue
- Nature Reviews Disease Primers
- Published
- 2025-03-06
- Volume
- 11
- Issue
- 1
- Pages
- 14-14
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4408204932
- Cited by
- 293
- References
- 355
- FWCI
- 73.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.